Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion

Core Insights - Kimberly-Clark has agreed to acquire Kenvue, the maker of Tylenol, for approximately $48.7 billion, resulting in an 18% increase in Kenvue's shares during premarket trading [1] - The merger aims to create a new consumer health giant, combining Kenvue's portfolio with Kimberly-Clark's well-known brands like Kleenex and Huggies [1][4] - Kenvue has faced challenges, including a decline in stock prices since its spin-off from Johnson & Johnson in 2023 and negative publicity surrounding Tylenol [2][1] Company Overview - Kenvue's stock was valued at about $40 billion in the deal, with Kimberly-Clark shareholders set to own 54% of the new entity [3] - The combined company is projected to have annual revenues of around $32 billion, leveraging both companies' iconic brands [4] - Kimberly-Clark CEO Mike Hsu emphasized that the merger positions Kenvue at the intersection of consumer packaged goods (CPG) and healthcare, serving billions of consumers [5]